SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than 8 years’ experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 300 features and breaking news articles, including multiple award-winning stories. Her particular focuses are neuroscience, rare disease and regulatory science. She has also traveled internationally to cover global biotech hubs, including Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, watching her American League champion Toronto Blue Jays, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Scales and paper balls as a symbol of positive and negative thoughts.
Regulatory
Capricor CEO won’t rule out legal action against FDA after negative adcomm
After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”
July 31, 2026
 · 
6 min read
 · 
Heather McKenzie
Solution and strategy path questions and clear planning for ideas in business leadership with a straight path to success choosing the right strategic plan with yellow traffic signs cutting through a maze of highways.
FDA
FDA advisers vote against approval of Capricor’s DMD therapy in chaotic adcomm meeting
During a perplexing advisory committee meeting in which FDA reviewers focused largely on the Phase 3 HOPE-3 trial’s secondary endpoint of cardiac function, experts pointed to “very fragile” data. The committee voted 9-3 against approval of deramiocel.
July 29, 2026
 · 
8 min read
 · 
Heather McKenzie
FDA
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
The FDA published briefing documents ahead of advisory committee meetings for therapies from Capricor Therapeutics and Replimune indicate an uphill battle for the biotechs; GSK and AstraZeneca outline ambitious plans in second quarter presentations; Sarepta taps Michael Severino as its new CEO; and Amgen launches its official defense of Tavneos.
July 29, 2026
 · 
1 min read
 · 
Heather McKenzie
Laptop with envelope and document with exclamation mark on screen. Receive notification, alert message, warning, get e-mail, email, spam concepts. Flat design vector illustration
FDA
UPDATE: FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy
In briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor’s assertion that a Phase 3 trial met its primary outcome measures.
July 27, 2026
 · 
3 min read
 · 
Heather McKenzie
Chess made from China and EU, USA flags. Europe Union, USA and China relations
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be required for Summit and China-based partner Akeso—and other transnational tandems—to secure FDA approval?
July 27, 2026
 · 
10 min read
 · 
Heather McKenzie
Arrows on a concrete wall. Red arrow, right direction. Stairs. Leadership concept. Team. Business Finance Background
Rare diseases
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follow to market Ionis Pharmaceuticals’ Tryngolza, which got the regulator’s nod in severe hypertriglyceridemia last month.
July 22, 2026
 · 
2 min read
 · 
Heather McKenzie
Podcast
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.
July 22, 2026
 · 
1 min read
 · 
Jef Akst
Psychology, Dream, Mental Health concept illustration. Brain, neuroscience and creative mind poster, cover. Vector modern illustration
Psychedelics
Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst cautioned, however, that the transaction should not be seen as “supporting a uniform re-rating of every psychedelic developer.”
July 20, 2026
 · 
3 min read
 · 
Heather McKenzie
Window cleaner using a squeegee to wash a window
Alzheimer’s disease
AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drug
New mid-stage data from Biogen’s Ionis-partnered therapy diranersen served to both validate the tau hypothesis in Alzheimer’s disease and raise questions that could soon be elucidated by anti-tau candidates from Denali Therapeutics, Eisai and Eli Lilly.
July 15, 2026
 · 
6 min read
 · 
Heather McKenzie
Podcast
Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Biogen’s new data, presented at the Alzheimer’s Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.
July 15, 2026
 · 
1 min read
 · 
Jef Akst
Progress success promotion and career growth Goal achievement, business woman walks up the stairs to the illuminated arrow. isometric vector illustration.
Alzheimer’s disease
AAIC 2026: Biogen delivers hope, validation with anti-tau Alzheimer’s win
Biogen touted an “unprecedented” drop in tau in a Phase 2 trial, backing the company’s decision to take diranersen to Phase 3 despite a missed primary endpoint and seemingly supporting the anti-tau approach.
July 14, 2026
 · 
5 min read
 · 
Heather McKenzie
Open Door in the room, interior background. Symbol of new way, exit, discovery, new opportunities. Business motivation concept, vector illustration
Huntington’s disease
Exit of Roche’s embattled Huntington’s drug ‘tightens’ case for Wave’s more selective ASO
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
July 13, 2026
 · 
4 min read
 · 
Heather McKenzie
Celebrating with trophy award for success or first place sporting championship win
FDA
Cancer, rare disease dominate FDA approvals in H1 2026 as AstraZeneca, J&J clean up
The FDA greenlit 26 novel therapies in the first half of 2026, including four for cancer and six for orphan indications. Meanwhile, AstraZeneca and Johnson and Johnson took home a combined 11 of the agency’s 79 total approvals, including supplemental nods.
July 9, 2026
 · 
1 min read
 · 
Heather McKenzie
Illustration Of Yacht Competing In Sailing Event
Rare diseases
Saol boards FDA’s resubmission boat, armed with new survival data
Saol Therapeutics is the latest biotech to resubmit for approval of a drug rejected under former FDA Commissioner Marty Makary, following REGENXBIO and Replimune.
July 9, 2026
 · 
3 min read
 · 
Heather McKenzie
One red lottery winner or rare disease, multi-level personification, power, reverse search, secret sample, special spy, close-up. Company leader
Rare diseases
Through flux and fluidity, FDA keeps coming back to rare disease
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
July 8, 2026
 · 
6 min read
 · 
Heather McKenzie